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Abstract
Galectin-3 is a human lectin involved in many cellular processes including differentiation, apoptosis, angiogenesis,
neoplastic transformation, and metastasis. We evaluated galectin-3C, an N-terminally truncated form of galectin-3 that is
thought to act as a dominant negative inhibitor, as a potential treatment for multiple myeloma (MM). Galectin-3 was
expressed at varying levels by all 9 human MM cell lines tested. In vitro galectin-3C exhibited modest anti-proliferative
effects on MM cells and inhibited chemotaxis and invasion of U266 MM cells induced by stromal cell-derived factor (SDF)-
1a. Galectin-3C facilitated the anticancer activity of bortezomib, a proteasome inhibitor approved by the FDA for MM
treatment. Galectin-3C and bortezomib also synergistically inhibited MM-induced angiogenesis activity in vitro. Delivery
of galectin-3C intravenously via an osmotic pump in a subcutaneous U266 cell NOD/SCID mouse model of MM
significantly inhibited tumor growth. The average tumor volume of bortezomib-treated animals was 19.6% and of
galectin-3C treated animals was 13.5% of the average volume of the untreated controls at day 35. The maximal effect was
obtained with the combination of galectin-3C with bortezomib that afforded a reduction of 94% in the mean tumor
volume compared to the untreated controls at day 35. In conclusion, this is the first study to show that inhibition of
galectin-3 is efficacious in a murine model of human MM. Our results demonstrated that galectin-3C alone was efficacious
in a xenograft mouse model of human MM, and that it enhanced the anti-tumor activity of bortezomib in vitro and in
vivo. These data provide the rationale for continued testing of galectin-3C towards initiation of clinical trials for treatment
of MM.
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Introduction
Multiple myeloma (MM) is a malignancy characterized by clonal
proliferation and accumulation of terminally differentiated plasma
cells that produce immunoglobulin (Ig). The malignant plasma cells
are found in the bone marrow and extramedullary locations. The
American Cancer Society estimated that there were more than
20,000 new cases of MM in the US in 2010. Currently
chemotherapyinduces complete tumorregression in50%of patients
but the median survival of MM is only about 5 years [1]. The
introduction of novel drugs such as thalidomide, lenalidomide, and
bortezomib (Bor) that are thought to target specific intracellular
pathways and affect cellular interactions with the tumor microen-
vironment, have aided in the treatment of MM especially in
management of elderly patients [2]. Nonetheless, arguably the
courseof the disease has not fundamentally changed since the 1960s.
During the last ten years, intriguing insights into the molecular
mechanisms underlying the progression of MM have been
obtained and successfully translated into more effective therapeu-
tics, such as the proteasome inhibitors [3]. Bor, a boronic acid
dipeptide, was the first-in-class proteasome inhibitor approved by
the US Food and Drug Administration (FDA) for the treatment of
relapsed and refractory MM [4–6]. Deregulation of the ubiquitin-
proteasome signaling pathway is linked to the etiology of various
human diseases and, therefore, proteasome inhibitors offer great
promise as therapeutic agents [7,8].
A human carbohydrate-binding protein that may play a role in
MM is galectin-3, a member of the galectin family that is defined
based on sequence homology within the carbohydrate recognition
domain (CRD) and a characteristic affinity for b-galactosides [9].
Galectin-3 can be variously located either intra- or extracellularly,
and is unique in the galectin family because in addition to the
carboxy-terminal CRD [10–12], it has an amino-terminal domain
that is critical for multivalent behavior. Alone, the carboxy-
terminal CRD has been reported to lack hemagglutination activity
and cooperative binding that are characteristics of the intact lectin
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21811[13]. The N-terminal domain enables the CRD to cross-link
carbohydrate-containing ligands on cell surfaces and in the
extracellular matrix and, thus, to modulate cell adhesion and
signaling [14]. There is striking evidence that galectin-3 plays a
role in neoplastic transformation, tumor growth, cancer cell
adhesion, metastasis, invasion, and apoptosis [15,16].
The truncated form of galectin-3 (Gal-3C) used in this study
consists of 143 carboxy-terminal amino acid residues of human
galectin-3. Gal-3C retains carbohydrate binding ability but lacks
the N-terminal domain and, therefore, is expected to act as a
dominant negative inhibitor of galectin-3 carbohydrate binding
and subsequent homophilic cross-linking mediated by the N-
terminal domain that promotes cell adhesion and consequent
survival signals [17].
The proteasome inhibitor Bor frequently becomes ineffective
in treatment of MM due to the development of drug resistance
and the drug also displays significant off-target toxicities [18]. In
an attempt to overcome these difficulties and to assess the
potential of Gal-3C as a treatment for MM, the present study
evaluated the efficacy of Gal-3C alone, and in combination with
Bor in NOD/SCID immunodeficient mice implanted with
human MM cells.
We found that Gal-3C inhibited the growth of MM U266
tumors in a subcutaneous murine model with activity that was
greater than Bor, and that combination of Gal-3C with Bor
further inhibited tumor growth. In addition, we show that in vitro
Gal-3C and Bor can synergistically inhibit MM-induced
angiogenesis.
Results
Galectin-3 is expressed by MM cell lines
Proteins derived from a panel of 9 human MM cell lines,
namely MM-1S, MM-1RL, NCI-H929, RPMI-8226, 8226/Dox-
40, 8226/LR-5, ARP-1, ARK-B, and U266, were analyzed by
Western blot to detect galectin-3 expression. Figure 1a indicates
that all of the cell lines expressed galectin-3 (,30 kDa). Expression
levels of monomeric galectin-3 in the cells differed, with U266 and
NCI-H929 having the highest levels.
The M3/38 anti-galectin-3 antibody also stained three other
bands that were present in most or all of the samples. Previous
studies indicate that this antibody binds to the N-terminal domain
of the full-length protein or to an N-terminal fragment of it [19].
Bands for two smaller proteins can be observed with one
somewhat greater than 20 kDa and the second at about 17 kDa.
Galectin-3 is subject to digestion by mammalian metalloprotei-
nases (MMPs) including MMP-2, -9, and -13 that primarily cleave
the Ala62 –Tyr63 bond yielding a fragment of ,22 kDa containing
the CRD and an N-terminal fragment [20,21]. The Gly32-Ala33
bond is an alternate site for cleavage by MMPs that yields a
27 kDa fragment containing the CRD [22].
Another band that appears at approximately 75 kDa in size is of
similar intensity in each sample. Galectin-3 can form non-covalent
homodimers and higher order multimers by binding mediated by
its N-terminal domain [23], and can form covalent homodimers
through intermolecular disulfide bonds of cysteine [24], and
through reactivity with tissue transglutaminase that catalyzes the
Figure 1. Galectin-3 expression levels in MM cell lines and effects of galectin-3 inhibition in vitro. (a) The lysates in each lane are as
follows: 1 MM-1S; 2 MM-1RL; 3 NCI-H929; 4 RPMI-8226; 5 Dox-40; 6 LR-5; 7 ARP-1; 8 ARB-B; 9 U266. Indicated MM cell lines were seeded at
300,000 cells/mL and maintained at 37uC and 5% CO2. Total protein fractions from exponentially growing cells were prepared and analyzed by
immunoblot to detect galectin-3. Galectin-3 monomers are approximately 30 kDa (arrow). Detection of bands at higher and lower masses is
consistent with reports of the multimerization of the protein and its digestion by matrix metalloproteinases. (b) Graph of the results from
proliferation assays shows the relative responses of MM-1S, MM-RL, NCI-H929, and RMPI-8266 and, (c) ARP-1, ARK-B, U266, and 8226/Dox cells to 0.5,
1, 2, or 4 mg/ml Gal-3C compared to control wells over 48 h. There was a significant decrease in proliferation in response to Gal-3C treatment (defined
as P,0.05; t-test) in all eight cell lines at one or more concentrations 48 h. Triplicate data points were analyzed and the data shown are representative
of 3 or more experiments. Error bars are6SD. (d) Graph of the results from proliferation assays with MM-1S, MM-RL, NCI-H929, and U266 showing the
relative response to 0.4, 2, 10,or 20 mg/ml Gal-3C compared to control wells over 24 h. There was a significant decrease (P,0.01) in proliferation of
MM-1S, NCI-H929, and U266 cells in response to Gal-3C at one or more concentration after 24 h. Error bars are6S.D.
doi:10.1371/journal.pone.0021811.g001
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electrophoresis, the samples were heated at 70 uC rather than
boiled, thus, it is also possible that the 75 kDa bands may be
composed of non-covalent homodimers of galectin-3. Transgluta-
mination should not be affected by reduction, but it is unlikely that
disulfide bonds would have survived the treatment of the samples
with the reducing agent, 2-mercaptoethanol.
Gal-3C inhibited the proliferation of MM cells
MM cell lines were plated in 96-well plates, Gal-3C was added,
and the relative proliferation determined after incubation of the
plates for either 24 or 48 h. Results from representative analyses
are shown in Figure 1b-d. Gal-3C inhibited the proliferation of all
eight cell lines at the 0.5, 1, 2, or 4 mg/ml concentration (b-c) after
48 h (P,0.05). Gal-3C treatment also significantly (P,0.01)
inhibited the proliferation of MM-1S, NCI-H929, and U266 but
not the MM-RL cell line at 0.4, 2.0, 10, or 20 mg/ml
concentrations at 24 h. The overall magnitude of the effects
observed with any of the cell lines was slight.
Chemotaxis of U266 MM cells was reduced by Gal-3C
The addition of Gal-3C to the media with U266 cells in the top
chambers of bicameral transwell chambers (Figure 2a) significantly
(P,0.001 for all Gal-3C treatments compared to controls) reduced
the migration of the cells into the bottom chamber containing
SDF-1a, a potent lymphocyte chemotactic factor [27]. The
percentage of inhibition increased by more than 70% using
2.0 mg/ml Gal-3C compared to a 0.4 mg/ml concentration.
However, increasing the concentration to 10 and 20 mg/ml
produced only a slightly higher percentage of inhibition compared
to 2.0 mg/ml.
Gal-3C inhibited the invasion of U266 cells and facilitated
Bor-mediated inhibition of invasion
To assess the ability of Gal-3C and Bor to inhibit the invasion of
MM cells, an assay was performed in 24-well TranswellH chamber
plates with 6.5-mm inserts containing polycarbonate membranes
with 5 mm pores coated with 50 ml Matrigel
TM (Becton Dickinson,
Bedford, MA, USA) [28]. After serum starvation for 3 h, U266
cells (5610
4) were added to the upper chambers with and without
Gal-3C (10 mg/ml), or Bor (5 nM), or the combination treatment.
To each lower chamber, 600 ml of media was added with 10%
FBS and 100 ng/ml SDF-1a. The U266 cells on the bottom of
each insert were Coomassie-stained and counted using a
microscope after incubating the plates at 37uC for 24 h. The
data as shown in Figure 2b revealed that both Gal-3C and Bor
treatments significantly decreased the invasion of the U266 cells by
more than 30% (P,0.05). In addition, there were significantly
fewer invaded cells in the wells treated with the combination of
Gal-3C plus Bor compared to wells treated with Gal-3C or Bor
alone (P,0.05). These results show that both Gal-3C and Bor
inhibited invasion by the U266 cells in vitro, and that the
combination treatment was more inhibitory than either alone.
Gal-3C and Bor synergistically inhibited endothelial cell
migration
To evaluate the effects of Gal-3C on MM cell-induced
migration of endothelial cells, a TranswellH-based chemotaxis
assay was performed as follows. U266 cells were cultured in media
in the presence of 10 mg/mL Gal-3C, 5 nM Bor, the combined
treatment, or vehicle (PBS)-only. After 48 h, conditioned media
(c.m.) derived from U266 cells given these different treatments
were diluted to 20% with EBM-2 medium and used as a
chemoattractant for human umbilical cord vascular endothelial
cells (HUVEC) cells. Without considering uptake by the U266
cells, the final concentration of drugs in the HUVEC chemotaxis
assay was 2 mg/mL Gal-3C and 1 nM Bor. Results of a 16-h
migration assay are displayed in Figure 3a and 3b. Single
treatments did not produce a significant variation in the migration
index, while the combined treatment resulted in an approximately
70% reduction of the HUVEC migration.
Gal-3C and Bor inhibited tubule formation in
angiogenesis assay
To evaluate the effect of different treatments on the ability of
U266 cells to induce angiogenesis, a Matrigel
TM-based tubule
formation assay was performed in the presence of U266 c.m. as
described for the chemotaxis assay. Serum-starved (5610
3)
HUVEC were seeded on the Matrigel surface in 200 mL EBM-2
medium supplemented with 20% V/V c.m. Pictures were taken
Figure 2. Gal-3C inhibits the chemotaxis and invasion of U266
MM cells. (a) Gal-3C (0.4, 2, 10, or 20 mg/ml) reduces the chemotaxis of
U266 cells in bicameral chambers in response to SDF-1a (100 ng/ml).
Error bars are6S.D. and sextuplicate data points are represented
(ANOVA with Tukey test P,0.001 for all compared to controls). (b) The
effect of Gal-3C and Bor on invasion activity of U266 cells. After
starvation in serum-free medium for 3 h, U266 cells were plated on
Matrigel-coated inserts in the upper chambers. The number of cells
which migrated through the Matrigel and filter from the upper chamber
and were adhering to the bottom of the insert were quantified by
counting using a microscope. Gal-3C (10 mg/ml) and Bor (5 nM), and the
combination of both significantly inhibited (P,0.05) U266 cell invasion.
Experiments were done in triplicate and repeated three times. Error bars
represent 6SD.
doi:10.1371/journal.pone.0021811.g002
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assay was run in triplicate and representative images are depicted
in Figure 3c. As a positive control, EBM-2 medium supplemented
with 20 ng/mL VEGF was also tested. Results indicate that
treatment with Gal-3C or Bor alone as well as in combination
almost completely impaired the potential of U266 cells for
induction of angiogenesis, as evidenced by the absence of the
organized tubule structures that were detectable only in the
control wells with VEGF-treated or untreated U266 cell-c.m.
Gal-3C did not affect endothelial cell viability
To determine if the apparent effects of Gal-3C alone or in
combination with Bor on vascular endothelial cell migration or
secretion were instead due to reduced cell viability, HUVEC cells
weretreated with Gal-3C,Bor,or bothagents for48 h. Viabilitywas
measured as described for the U266 cells. Because at the highest
concentrationstested, Gal-3Chad a mild effecton HUVEC viability
and Bor alone showed dramatic inhibition, lower concentrations of
Gal-3C (2 mg/ml) and Bor (1 nM) were used for the chemotaxis and
angiogenesis assays. Results obtained from the HUVEC viability
experiments that were run in triplicate are depicted in Figure 4, and
are presented as a percentage of control (untreated) cells.
Gal-3C and Bor reduced anb3 integrin clustering in
HUVEC cells
To evaluate the effects of different treatments on the ability of U266
cells to induce integrin engagement on endothelial cells, HUVEC
were incubated with c.m. obtained from U266 cells cultured in 10 mg/
mL Gal-3C, 5 nM Bor, or the combination (as described for the
chemotaxis assay) for 48 h. Confocal photomicrographs were taken
after immunofluorescence staining for anb3 integrin. Formation of
clusters indicates integrin engagement and it is evidenced as higher
fluorescence intensity. Figure 5 shows that Gal-3C and Bor, as well as
the combination treatment, were able to block the formation of
clusters of anb3 integrins that were detected only in wells incubated
with c.m. derived from untreated U266 (control) cells. No clusters
were evidenced without the addition of c.m. (EGM-2 only).
Gal-3C and Bor inhibited secretion of VEGF and bFGF by
U266 MM cells
A direct enzyme-linked immunoabsorbent assay (ELISA) was
performed to measure the levels of VEGF and bFGF in media
from U266 cells treated with 10 mg/mL Gal-3C, 5 nM Bor, Gal-
3C with Bor, or control media with vehicle (PBS) only for 16 h.
Figure 3. Vascular endothelial cell migration and tubule formation. (a)5 610
4 serum-starved HUVEC cells were loaded in the upper chamber
of a Transwell
H plate (8 mm-diameter pores). The bottom chamber was filled with 600 mL serum-free EBM-2 medium supplemented with 20% V/V
conditioned (c.m.) derived from U266 cultures undergone different treatments: control (ctrl), Gal-3C, Bor, or Gal-3C and Bor combined (Gal-3C+Bor).
EBM-2 medium alone was used as a negative control. After 16-h incubation, chamber filters were removed and migrated cells were fixed and stained
with Coomassie brilliant blue as described in Materials and Methods. Mean migration indices (error bars are6SD) were expressed as the number of
cells migrated in the presence of the indicated stimulus divided by the number of cells migrated in the presence of EBM-2 alone. One-way ANOVA
and Tukey’s post-test indicated that Gal-3C+Bor migration index was significantly different from control (*P,0.001), while no significant difference
was detected between the control and Gal-3C or Bor alone (P.0.05). All assays were run in triplicate. (b) representative pictures of the filters. (c)
5610
3 serum-starved HUVEC were allowed to form tubules on a Matrigel
TM surface for 16 h in the presence of VEGF (positive control), EMB-2 medium
alone (negative control), or EBM-2 supplemented with 20% V/V U266 c.m. Representative pictures from 3 comparable experiments are shown.
doi:10.1371/journal.pone.0021811.g003
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curves obtained by analysis of 10-fold serial dilutions (0-
1,000 ng/mL) of the purified recombinant proteins (Abcam,
MA, USA). Figure 6 shows the results from 3 independent
experiments. Gal-3C alone significantly reduced VEGF but not
bFGF levels, while Bor alone or in combination with Gal-3C
significantly reduced both VEGF and bFGF levels.
Generation and testing of AAV/GFP virus stocks
A structural map of the adeno associated virus (AAV)/GFP
vector is presented in Fig. S1a. The restriction sites XbaI and NotI
were used to insert the GFP gene downstream of the p5 promoter.
Panel b illustrates the identification of AAV/GFP by restriction
enzyme analysis. GFP was cut from AAV/GFP by XbaI and NotI
enzymes. The titer of virus stocks was determined by real-time
PCR to be 10
8 encapsulated genomes (Fig. S1c). After generation
of the AAV/GFP virus stock, we evaluated the infection of U266
cells. The AAV/GFP vector-infected cells expressed GFP, as
confirmed by cytofluorimetric analysis, RT-PCR and immunoflu-
orescence labeling (Fig. S1d-f).
Growth of U266 tumors was inhibited by Gal-3C alone
and Gal-3C with Bor
The sequence of procedures used to establish the U266 MM
model in the NOD/SCID mice and to treat the mice with Gal-3C,
Bor, and the combination of Gal-3C and Bor is shown in
Figure 7a. Tumor volumes (Figure 7b) were measured with
calipers once weekly. Treatment with vehicle, monotherapy with
Gal-3C or Bor, or combination therapy began on d 14.
The average tumor volume in the Bor-treated group was
significantly less than in the untreated group from d 28 through d
35 (unpaired t test P,0.001), while Gal-3C and Bor+Gal-3C
groups displayed tumors significantly smaller than untreated
animals (82% and 61%, respectively) as soon as d 21 (unpaired t
test P,0.001). At d 35, the average tumor volumes of the Gal-3C-
only and the Bor-only group were 13.5% and 19.6% that of the
untreated controls, respectively.
The average tumor volume in the groups receiving the
combination of Gal-3C with Bor was significantly less than that
of the groups treated with Bor (or with Gal-3C) beginning on d 21
(unpaired t test P,0.001). Gal-3C treatment produced a
Figure 4. Vascular endothelial cell viability assay. Viability was
measured as described for U266 cells in experiments run in triplicate
and displayed as percentage of control (untreated) cells. The graphs
show mean values and error bars represent6SD. **ANOVA Tukey’s post
test P,0.01. n.s.=not significant.
doi:10.1371/journal.pone.0021811.g004
Figure 5. anb3 integrin clustering assay. After culturing for 48 h with 20% V/V U266 c.m., HUVEC cells were fixed and stained with anti- avb3
antibody. Integrin clusters are evidenced as high density spots in the HUVEC treated with U266 c.m. (I), but not when HUVEC were incubated with
c.m. derived from U266 treated with Gal-3C (II), Bor (III), or Gal-3C+Bor (IV). Clusters were also absent in HUVEC treated with EGM-2 medium alone (V).
The figure shows representative photomicrographs obtained by confocal microscopy (60X magnification) from three independent experiments.
doi:10.1371/journal.pone.0021811.g005
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on d 21 (unpaired t test P,0.001), with a mean difference between
the two of 4.43161.494 mm
3, through d 35 when the mean
difference was 31.5464.379 mm
3 (unpaired t test P,0.001). The
maximum effect was observed on d 35, when the combination
therapy afforded a reduction of 94% in the mean tumor volume,
compared with the untreated group (unpaired t test P,0.001).
Specimens of the subcutaneous tumors were analyzed for
mRNA encoding AKAP-4 and GFP by RT-PCR weekly. The
results (Figure 8) demonstrated the expression of both GFP and
AKAP-4 and confirmed that the tumor masses originated from
U266 cells. The expression levels of AKAP-4 and GFP in the Gal-
3C plus Bor group were lower than any of the other groups at d
35.
AKAP-4 also was detected in the sera of tumor-bearing mice
(Figure 9 bottom panel). Tumor growth was associated with
increased AKAP-4 levels in the serum beginning in the vehicle-
only group on d 21. At 35 d after inoculation, AKAP-4 in the sera
from the combination therapy (Gal-3C plus Bor) group was lower
than the PBS group.
Tumor expression of human IgE and Igl was diminished
in treated groups
The presence of human Ig in the sera of the tumor-bearing
mice was confirmed by ELISA and flow cytometry (Figures 9
and 10). The tumors expressed human IgE and Igl,w h i l e
human IgG and Igk were very low level in either the tumors or
the sera of the mice. Moreover, the expression levels of IgE and
Igl in the treated groups (Figure 9 top and middle panel,
respectively) were significantly less (P,0.05) than the levels in the
controls. The lowest expression levels of IgE and Igl were
observed in the tumors of the group treated with Gal-3C with
Bor.
Flow cytometric analyses confirmed the expression of IgE and
Igl by the tumors (Figure 10), and revealed that the highest
expression levels of IgE, Igl and AKAP-4 were in the tumors of
the PBS-only control group. The levels of all three were lowest in
the group treated with the combination of Gal-3C with Bor, a
result that reflected the results from the analysis of the tumor
volumes of the groups.
Discussion
Current treatment for MM is based on high-dose chemother-
apy, radiotherapy, and autologous hematopoietic stem cell
transplantation. What triggers MM is not well understood and
since fatal relapses are routinely observed even after complete
remissions, it remains a fatal hematological disease [29].
The proteasome inhibitor Bor was approved for the treatment
of relapsed and refractory MM by the FDA in 2003 [30], but dose-
limiting toxicities and the development of resistance often prevent
its long-term use. Notably, although Bor alone or in combination
with other agents, such as thalidomide or lenalidomide, provides
up to 85% response rates, nearly 100% of patients eventually
relapse [29]. These findings underscore the urgent need to develop
new multiple-targeted therapies for more effective treatment of
MM.
In the present study, we evaluated the efficacy of monotherapy
with Gal-3C, which is an N-terminally truncated form of galectin-
3, and Gal-3C in a combination therapy with Bor in a NOD/
SCID mouse model harboring human MM.
Immunoblot analysis of human MM cell lines revealed that all
of the cell lines expressed at least a low level of galectin-3, and that
NCI-H929 and U266 cells displayed the highest levels (Figure 1a).
The U266 cells were chosen for the animal model because of their
relatively high expression level of galectin-3. Varying levels of
galectin-3 fragments were observed in the cell lines and were
highest in the mephalin-resistant 8226/LR-5 cells.
Galectin-3 is a substrate for MMP digestion. Recent reports
have shown that peptides corresponding to galectin-3 fragments
formed by MMP cleavage that contained the CRD but which
were longer than Gal-3C increased tumor growth and angiogen-
esis in breast cancer xenograft models [22]. Testing various
galectin-3 fragments showed that greater endothelial cell chemo-
taxis and more capillary-like morphogenesis were induced by
peptides corresponding to the N-terminal 1–62 amino acids and a
molecule containing the CRD corresponding to amino acids 33–
250 [31]. Prostate specific antigen (PSA) is a chymotrypsin-like
serine protease in human seminal plasma that has been shown to
cleave galectin-3 between Y
107-G
108 which would yield the Gal-3C
of this study, and the corresponding N-terminal domain [32],
suggesting that Gal-3C is unlikely to be very antigenic in humans.
Figure 6. Molecular effects of Gal-3C and Bor on U266 cells. After 48 h in the presence of indicated treatments, the c.m. of U266 cells was
diluted 1:2 in ELISA coating buffer and used in a direct ELISA for the measurement of VEGF and bFGF. Histograms represent mean values of 3
independent experiments. Error bars indicate6SD. Statistical analysis was performed through one-way ANOVA and Tukey’s post-test: **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0021811.g006
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the proliferation of all 8 MM cell lines tested. We postulate that
this effect on proliferation was due to inhibition of galectin-3 which
contains the NWGR domain characteristic of the Bcl-2 family [33]
and has been shown to inhibit apoptosis [34] and increase
chemoresistance in cancer [35]. However, the sensitivity of the
NCI-H929 and U266 cell lines, which had the highest expression
levels of monomeric galectin-3, was no greater than that of the
other MM cell lines. Also, there was little dose-response effect
observed likely due to increased Gal-3C multimerization at higher
concentrations. Although self-association through the N-terminal
domain when galectin-3 is bound to cell surface glycoconjugates
has been reported to cause the aggregation of various types of cells
[36,37], lactose-inhibitable homodimerization mediated by the
CRD has also been observed [38]. The possibility that the primary
activity of Gal-3C in the in vivo model may be mediated by
Figure 8. Analysis of AKAP-4 and GFP expression. RT-PCR showing the expression of AKAP-4 and GFP in the tumor masses in the four groups
(5 mice/group): (1) U266 (2) no RT (3) no template (4) d 21 (5) d 28 (6) d 35. The U266 cell line was used as a positive control after culture for 48-h.
doi:10.1371/journal.pone.0021811.g008
Figure 7. Experimental design and outcome of Gal-3C treatment in NOD/SCID MM xenografts. (a) The diagram shows the timing of
tumor challenge, drug administration, and sample collections. (b) Gal-3C reduced the growth of U266 MM tumors as a single agent, and in
combination with Bor significantly reduced the MM tumor growth compared to treatment with either agent alone. The primary tumors were
measured weekly with calipers after subcutaneous inoculation of mice with U266 cells. The results represent the combination of 3 separate
experiments with n=5 mice per group in each experiment, and the error bars represent6SEM. The mean tumor volume in the Bor-treated group was
significantly less than in the untreated group from d 28 through d 35 (unpaired t test P,0.001). The mean tumor volume in the group treated with
Gal-3C alone also was significantly less than that in the group treated with Bor alone from d 21 through 35 (unpaired t test P,0.001). At d 35, the
mean tumor volumes of the Gal-3C-only and the Bor-only group were 13.5% and 19.6% that of the untreated controls, respectively. (c) Representative
images are presented illustrating the difference between the groups in tumor size after 35 d.
doi:10.1371/journal.pone.0021811.g007
New Multiple Myeloma Treatment with Galectin-3C
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21811interactions involving the tumor environment rather than by direct
cytotoxicity to the MM cells is supported by our finding that the
modest sensitivity of the MM cells to Gal-3C did not appear to
depend on their galectin-3 expression levels.
The localization and retention of MM cells in the bone
marrow is a hallmark of MM although the small numbers of
MM cells found in the circulation are thought to represent the
tumor-spreading component. The number of circulating cells
increases at the end stage of disease, when MM cells are thought
to gain the ability to proliferate outside of the bone marrow
microenvironment and grow at extramedullary sites [39]. Thus,
the processes of chemotaxis and invasion play a role in the
pathophysiology of MM.
As shown in Figure 2a, Gal-3C at 2.0 mg/ml inhibited more
than 60% of the U266 cell chemotaxis stimulated by the
chemokine, SDF-1a. The SDF-1a and its receptor, CXCR4, are
regulators of the migration and homing of MM cells to the bone
marrow, and possibly may also control egression of MM cells out
of the bone marrow [40]. Previously, galectin-3 was shown to
induce the migration of monocytes, macrophages, and dendritic
Figure 9. ELISA for human immunoglobulins and AKAP-4 in mouse sera. The mice were bled at the indicated time point after inoculation of
U266 cells, and the levels of IgE heavy (A) and light chains (B), and AKAP-4 (C), were determined by ELISA. The levels of heavy and light chain IgE and
AKAP-4 were significantly lower in the treated groups than in the PBS group (P,0.05) on d 21, 28, and 35, and the levels in the Gal-3C plus Bor
animals were the lowest of any group. Each graph is representative of three experiments with samples analyzed in triplicates, and the error bars
represent6SD.
doi:10.1371/journal.pone.0021811.g009
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galectin-3 and was shown to inhibit VEGF-induced chemotaxis of
MM-1S MM cells when at the 200–400 mg/ml concentration
[42].
Gal-3C at 10 mg/ml and Bor at 5 nM inhibited more than 30%
of U266 cell invasion of Transwell chamber inserts with 5 mm
pores that were coated with Matrigel as shown in Figure 2b.
Invasion in this assay also was induced by SDF-1a in the bottom
chamber. When Gal-3C was combined with Bor, more than 60%
of the U266 cell invasion was inhibited. To our knowledge this is
the first report that inhibition of galectin-3 can reduce the
invasiveness of MM cells.
Angiogenesis plays a key role in the interactions between MM
cells and their microenvironment [43–45], and recent data suggest
that VEGF is the main mediator of MM-induced angiogenesis
[46–48]. Galectin-3 has been shown to facilitate, and Gal-3C to
inhibit VEGF-mediated angiogenesis [49]. Importantly, increased
angiogenesis has been found to be indicative of poor prognosis in
MM patients [45,50,51]. Thus, we postulated that the effects of
Gal-3C in vivo could be at least partly due to inhibition of
angiogenesis induced by the engrafted U266 cells, and tested this
postulate using in vitro HUVEC migration and angiogenesis assays.
Our results show that the media derived from U266 cells treated
with Gal-3C in combination with Bor induced significantly less
HUVEC migration and angiogenesis as revealed by tubule
formation in vitro compared to media derived from untreated
U266 cells (Figure 3). The single treatments significantly inhibited
angiogenesis (tubule formation) but not HUVEC migration. We
eliminated the possibility that the inhibition observed was due to
reduced HUVEC viability, since Gal-3C did not display significant
effects on HUVEC viability at the concentration used in the
chemotaxis and angiogenesis assays, and Bor had an effect only at
a concentration 5-fold higher (Figure 4). Furthermore, at the
concentration used in HUVEC assays, Bor did not display any
effect on HUVEC viability when combined with different
concentrations of Gal-3C (Figure 4).
Because anb3 integrin engagement has been shown to be
required for angiogenesis [52], we tested the ability of c.m. derived
from differently treated U266 cells to induce anb3 integrin
activation in HUVEC cells. Figure 5 shows that the combined, as
well as the single treatments, effectively blocked anb3 integrin
activation, as evidenced as protein clusters [49]. This result is in
accordance with the observation that single and combined Gal-3C
and Bor treatments were able to hamper tubule formation induced
by U266 c.m. (Figure 3c).
ELISA assays showed that Gal-3C and Bor alone or combined
significantly reduced U266 ability to secrete VEGF, but a
significant decrease in bFGF levels was observed only with Bor,
alone or combined with Gal-3C (Figure 6). These observations
suggest that the ability of Gal-3C and Bor to hamper HUVEC
migration and in vitro angiogenesis is at least in part due to down-
regulation of VEGF and bFGF.
Gal-3C had more efficacy than Bor as a single agent when
delivered intravenously using an osmotic mini-pump in NOD/
SCID mice based on differences in tumor volume at the end of the
study (d 35, P,0.001). Importantly for potential clinical
applications, the combination of Gal-3C with Bor significantly
reduced tumor growth (P,0.001) compared to treatment with
either agent alone beginning from d 28.
In our previous study in a CD-1 nude mouse model of
metastatic human breast cancer [17], Gal-3C (125 mg/dose) was
injected intramuscularly twice daily whereas in the current study,
approximately 30 mg/d was administered daily using an osmotic
pump for continuous delivery. Our data suggest that sustained
delivery may be preferable for maximal response to treatment,
which is supported by our previous finding that the half-life of Gal-
3C in mice was only approximately 3 h [17].
In addition to monitoring disease progression by measuring the
tumors with calipers, the levels of human IgE and Igl in the sera
of tumor-bearing mice were analyzed by ELISA and found to be
higher in comparison to control mice, consistent with the in vivo
expansion of the U266 cells that secrete IgE [53]. Contempora-
neously, AKAP-4, a member of scaffolding protein family, was
used as a tumor marker. Heavy and light chain IgE and AKAP-4
levels were significantly lower in treated groups compared to the
PBS group on d 21, 28, and 35. The levels of human IgE and Igl
in both the serum and tumor mass were lower in the Gal-3C plus
Bor group compared with all other groups. These results support
the differences observed between the groups from the tumor
volume measurements. These results were also confirmed by
cytofluorimetric analysis of IgE and Igl on cells from tumor
masses (Figure 10), and are in accordance with the increased levels
Figure 10. Flow cytometric analyses of the expression of IgE, IgG, Igk,I g l, and AKAP-4. Cells from liver, blood, and tumor masses of
animals from each group were minced under sterile conditions at RT to obtain single-cell suspensions. Histograms show the mean fluorescence
intensity (MFI) and the error bars indicate6SD calculated from 3 independent experiments with samples analyzed in triplicates. The results show that
IgE, Igl, and AKAP-4 were expressed by the tumor cell; Igk and IgG were expressed at very low levels. Expression levels of IgE, Igl, and AKAP-4 in the
PBS control group were the highest, while the levels in the tumors of the group treated with the combination of Gal-3C with Bor were the lowest.
doi:10.1371/journal.pone.0021811.g010
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diagnosis and prognosis [54-56].
Our prior study investigating AKAP-4 expression in MM and in
normal tissues demonstrated that it is a novel MM tumor-
associated antigen [57]. Both AKAP-4 and GFP were detected in
all tumor masses. The expression of AKAP-4 and GFP was the
lowest in animals treated with Gal-3C plus Bor, mirroring the
results obtained with IgE and Igl and caliper measurements.
Moreover, the results obtained with the two different markers GFP
and AKAP-4 were concordant, further confirming that AKAP-4 is
a novel, reliable biomarker for MM.
These data demonstrate that serum levels of the human
monoclonal Igs and AKAP-4 can be used to monitor MM
progression in vivo in murine models and aid in the pre-clinical
evaluation of new anti-myeloma therapies. An advantage of
AKAP-4 for clinical use would be that the serum levels of the
protein are normally very low in humans, unlike human Ig.
There is evidence that members of the galectin family other
than galectin-3 [49], such as galectin-1 [58] and galectin-8 [59]
induce angiogenesis and are tumorigenic. Galectin-1 is involved in
cell cycle regulation, apoptosis, cell migration, and tumor evasion
of immune responses [58,60]. Galectin-8 promotes cell adhesion
by binding cell surface integrins [61], and its levels have been
correlated with cancer progression [61].
Tumor growth and metastasis were suppressed in mice lacking
Mgat5, an enzyme forming antenna-like oligosaccharides contain-
ing lactosamines [62]. Mgat5-extended poly-N-acetyllactosamine
(poly-LacNAc) binding sites typically have two or more LacNAcs
[63]. As a dominant negative inhibitor, Gal-3C would block
carbohydrate binding sites of some other members of the galectin
family. For example, comparing dissociation constants determined
by frontal affinity chromatography, Gal-3C has been more affinity
for LacNAc2, (Kd=4.8 mM), LacNAc3, (Kd=0.87 mM) and
LacNAc5, (Kd=0.43 mM) than galectin-1 (Kd=50, 45, and
39 mM, respectively) and similar or more affinity than galectin-8
(Kd=3.5, 9.6 and 1.6 mM, respectively) [63].
The translational potential of our results is evident when
considering that neovascularization of bone marrow is thought to
support the progression of MM and that inhibition of angiogenesis
is one of the key mechanisms of action of several current frontline
drugs for MM therapy, such as thalidomide [64,65], lenalidomide
[66] and Bor itself [65,67], indicating that inhibition of blood
vessel formation might account for the synergistic effect of Gal-3C
and Bor observed in vivo. Notably, it has been previously shown
that galectin-3-mediated m anb3-integrin clustering and activation
in HUVEC cells are required for cell migration and angiogenesis
[49], but this is the first time that galectin-3 has been reported to
control the angiogenic potential of MM cells by modulating the
expression of VEGF. The mechanism of the Gal-3C-mediated
down-regulation of VEGF will be subject of future investigations.
The mechanism of action of Bor has been found to be more
complex than originally thought. In MM cells specifically, Bor has
been shown to induce the canonical NF-kB pathway by triggering
IKKb-mediated phosphorylation of IKBa [68]. This effect
potentially reduces the therapeutic effect of Bor, because NF-kB
activation in plasma cells is associated with anti-apoptotic
pathways [68]. Accordingly, IKK inhibitors potentiate Bor
cytotoxicity in vitro and the therapeutic combination of Bor with
the IKK inhibitors PS-1145 and MLN120B has been proposed
[68]. Previous reports show that galectin-3 can induce the NF-kB
pathway and activation of downstream target genes [69], and that
inhibition of galectin-3 with modified citrus pectin (GCS-100) [42]
impairs TNF-a induced activation of NF-kB by hampering IKKa
phosphorylation of MM cells [70]. In future studies we will
examine the effect of Gal-3C on the Bor-mediated induction of the
NF-kB pathway in MM cells.
An advantage of our approach is that Gal-3C appears to have a
low toxicity profile [17] but is nonetheless capable of chemosensi-
tizing MM cells. Our work indicates that Gal-3C can inhibit the
proliferation, chemotaxis, and invasiveness of MM cells, and MM-
cell induced angiogenesis, and provides the first evidence of the
effectiveness of Gal-3C in combination therapy in vivo in an animal
model of human MM where we also showed that Gal-3C was
more effective than Bor as a monotherapy. Our data indicate that
Gal-3C potentially may help to fulfill the need for new targeted
therapies for the treatment of MM [71]. The significance of our
approach is highlighted by recent findings that agents able to block
the vicious cycle generated by the complex interactions between
MM cells and their microenvironment may prove to be a key in
future management of this still incurable disease [71]. Gal-3C has
previously shown anticancer activity in a mouse model of
metastatic breast cancer, and is thought to act through inhibition
of functionality of galectin-3 which has been strongly implicated in
the progression of cancer. Our results provide proof-of-principle
for the activity of Gal-3C in MM that justifies continued
investigation aimed at the initiation of clinical testing.
Materials and Methods
Animals
Six-week-old female NOD.CB17-Prkdcscid/J (NOD/SCID)
mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). All mice were maintained in filtered-air laminar-flow
cabinets under specific pathogen-free conditions. Treatment and
care were in accordance with the Institutional Guidelines of the
Texas Tech University Laboratory Animal Resources Center
(LARC) and the Animal Welfare Assurance Act. All mice were
euthanized before they were 10 weeks of age.
Cells and media
The human MM cell lines used in this study were RPMI-8226,
U266 (American Type Culture Collection, Manassas, VA, USA),
ARP-1, ARK-B, (gifts from J. Epstein, University of Arkansas for
Medical Sciences, Little Rock, AR, USA). The MM cell lines
MM.1S and MM.1RL were generously provided by Dr. Steven T.
Rosen, of Northwestern University in Evanston, Illinois [72], and
the NCI-H929 cell line was donated by Dr. Steven D. Rosen of
the University of California, San Francisco. The 8226/Dox and
8226/LR-5 cell lines were kindly provided by Dr. William S.
Dalton of the H. Lee Moffitt Cancer Center and Research
Institute in Tampa, Florida [73]. All MM cells were cultured in
RPMI-1640 medium supplemented with 10% fetal bovine serum
(FBS) in 5% CO2 at 37uC. The 8226/Dox cells were cultured with
40 nM doxorubicin (Sigma-Aldrich, St. Louis, MO, USA). The
8226/LR-5 cells were cultured in media containing 5 mM
mephalan (Sigma-Aldrich). 8226/Dox and 8226/LR-5 cells were
maintained in drug-free medium for 1 week prior to drug
sensitivity assays. HUVEC (American Type Culture Collection)
were maintained in EGM-2 medium (Lonza, Houston, TX, USA)
and were used within 10 passages.
SDS-PAGE and immunoblot
MM cells were harvested and washed twice with PBS. Cell lysis
buffer was prepared by mixing 2 ml of M-PER protein extraction
buffer (Pierce/Thermo, Rockford, IL, USA) with 40 ml of Protease
Inhibitor Cocktail (Sigma-Aldrich). The cell suspensions were
transferred to a new tube, homogenized using a handheld mortar
and pestle, and then rocked at room temperature (RT) for 10 min.
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15 min, diluted to a final concentration of 2.5 mg/ml protein
using M-PER, LDS buffer (Invitrogen, Carlsbad, CA, USA), and
the reducing agent, 2-mercaptoethanol, and then heated at 70uC
for 10 min. Proteins were resolved on 4–12% Bis-Tris (Bis(2-
hydroxyethyl)-amino-tris(hydroxymethyl)-methane) polyacryl-
amide gel (Invitrogen) and then electrotransferred onto 0.2 um
nitrocellulose membrane. After rinsing in PBS-Tween, the blot
was stored in protein-free blocking buffer (Pierce/Thermo) at 4uC
overnight. Then, the blot was incubated with anti-galectin-3
antibody [74] (M3/38, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) diluted 1:200 in blocking buffer at RT for 30 min. After
washing 5 times with PBS-Tween, the blot was incubated with
biotin-conjugated anti-rat IgG diluted 1:2000 in blocking buffer at
RT for 1 h. After 5 washings, the blot was incubated with
horseradish peroxidase-conjugated streptavidin diluted 1:1000 in
blocking buffer at RT for 20 min, and then developed with
3,39,5,59-tetramethylbenzidine (TMB) with membrane enhancer
(KPL; Mandel Scientific, Guelph, Canada). Images were captured
with a digital camera and digitally enhanced (Adobe PhotoShop or
ImageJ).
Drugs and mini-pumps
Gal-3C was prepared as previously described [17]. Bor was
purchased from Millennium Pharmaceuticals (Cambridge, MA,
USA). Doxorubicin and mephalan were obtained from Sigma-
Aldrich. The 200-mL 2002 mini-osmotic pumps designed to
deliver 0.5 mL/h were purchased from DURECT Corporation
(Cupertino, CA, USA).
Cell proliferation and viability
Cell proliferation was assessed with a ViaLight Plus Cell
Proliferation and Cytotoxicity BioAssay Kit (Lonza, Walkersville,
MD, USA) according to the directions of the manufacturer. In
brief, myeloma cells were seeded (8,000 per well) in 50 mlo f
RPMI-1640 with 10% heat-inactivated FBS (growth medium) in
96-well plates. HUVEC cells were seeded (10,000/well) in 50 ml
EGM-2 medium in 96-well plates. Gal-3C (2X concentration) in
50 mL of growth medium was added to triplicate wells and the
plate kept at the CO2 incubator at 37uC for 24 or 48 h. For the
ViaLight assay, 50 mL of lysis buffer was added to each well, the
plate was incubated for 10 min, after which 50 mL of cell lysate
from each well was transferred to a solid white Lumitrac-200 plate
and 50 mL of reconstituted AMR Plus was added. Luminescence
was measured with a 1-s integrated setting in a Berthold
luminometer after 2 min. With Alamar Blue, 10 mL of reagent
was added per well and the plate kept in a CO2 incubator for 4 h.
Fluorescence intensity was measured at 590-nm on a Polarstar
Galaxy (BMG Labtech, Cary, NC, USA) microplate reader. The
blank (growth media with 10 ml Alamar Blue) was subtracted from
the raw fluorescence to obtain adjusted fluorescence readings.
Chemotaxis assays
U266 cells (400610
3/well) were plated in 100-ml cell culture
media with and without Gal-3C (0, 0.4, 2.0, 10, and 20 mg/ml) in
the top chambers of 24-well transwell inserts with 8-mm pores. Cell
culture medium (600 ml) containing the B-cell chemoattractant
SDF-1a (100 ng/ml; R&D Systems, Minneapolis, MN, USA) was
added to the bottom chamber. After 4 h, the U266 cells in the
bottom chamber were counted with a FACScan flow cytometer
(flux rate on high, a 2 min acquisition gate, and 200 ms resolution).
For HUVEC cells, chemotaxis was analyzed as reported [49],
using 50610
3 cells/well and 24-well transwell inserts with 8-mm
pores. The lower chamber was filled with 600-ml EGM-2 medium
supplemented with 20% V/V c.m., obtained after treatment of
U266 cells with 10 mg/mL Gal-3C, 5 nM Bor, or 10 mg/mL Gal-
3C with 5 nM Bor for 48 h, or with 0.6% V/V PBS (vehicle) as a
control. As a negative control, EGM-2 medium alone was used.
After incubation for 16 h, cells were removed from the upper
chamber, and the migrated cells were visualized on the lower side
of the filter after fixing and staining with 30% methanol, 10%
acetic and 0.1% Coomassie Brilliant Blue. Next, the filters were
extensively washed with water, and then air-dried and photo-
graphed using an inverted X71 microscope (Olympus, Center
Valley, PA, USA). The average number of cells in 4 random fields
per filter was calculated. The experiments were run in triplicate
and the results are expressed as a migration index (MI), as follows:
MI=number of cells migrated in the presence of c.m./number of
cells migrated in the presence of EGM-2 alone.
Invasion assay
An invasion assay was performed with U266 cells in 24-well,
6.5-mm internal diameter TranswellH chamber plates with
polycarbonate membranes (5-mm pore size, Corning Costar, NY)
as described previously [28]. Briefly the upper chambers were
coated with 50-ml Matrigel (Becton Dickinson, Bedford, MA,
USA) in advance according to the directions of the manufacturer.
U266 cells (5610
4) in suspension were starved in serum-free
RPMI-1640 for 3 h, and then loaded onto the Matrigel-coated
inserts in the upper chambers. The lower chamber of the transwell
was filled with 600-ml of 10% FBS-containing cell culture media
with 100 ng/ml SDF-1a. Gal-3C (10 mg/ml), Bor (5 nM), Gal-3C
with Bor, or PBS vehicle-only were added with the cells to the
upper chamber. At the 5 nM concentration used, the cytotoxicity
of Bor for the U266 cells was expected to be minimal [75]. Plates
were then incubated at 37uC for 24 h. At the end of the incubation
period, non-invasive cells on the top of the transwell were scraped
off with a cotton swab. Cells that had invaded the bottom chamber
were fixed in methanol, stained with Coomassie, and then counted
using a light microscope as described above for the chemotaxis
assay.
Tubule formation assay
A tubule formation assay was performed in vitro as described
[49] to measure angiogenesis. Briefly, growth factor–reduced
Matrigel (50 mL/well; Becton Dickinson) was allowed to polymer-
ize in the presence of 30 ng/mL recombinant basic fibroblastic
growth factor (bFGF; R&D Systems) for 1 h at 37uC. HUVECs
(5,000/well), serum-starved for 2 h prior to trypsinization, were
resuspended in 200-mL serum-free EGM-2 supplemented with
20% V/V c.m. obtained after treatment of U266 cells with 10 mg/
mL Gal-3C, 5 nM Bor, the combination treatment, or 0.6% V/V
PBS (vehicle) as a control for 48 h. The positive control was EGM-
2 with 20 ng/mL VEGF (R&D Systems) [76], while the negative
control was EGM-2 alone. Cells were seeded onto the polymerized
Matrigel and incubated at 37uC with 5% CO2 for 16 h to allow
tubule formation. The assays were run in triplicate, and
microphotographs were taken with an inverted X71 microscope
(Olympus).
amb3 Integrin cluster formation assay
HUVECs were cultured in 8-chamber slides coated with 10 mg/
ml fibronectin (10
4 cells/chamber). Cells were incubated with c.m.
for 20 min, and fixed with 4% paraformaldehyde in PBS (10 min
at 37uC). Then, cells were incubated with 10 mg/ml anti-integrin
avb3 antibody (R&D Systems, 1:200 dilution in PBS) for 1 h at
RT, followed by the addition of FITC-anti–mouse IgG (1:1000
dilution in PBS) for 1 h at RT. Microphotographs of randomly
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microscopy.
ELISA for VEGF and bFGF
The levels of VEGF and bFGF were measured by direct ELISA
as follows. Flat-bottom 96-well polycarbonate plates were coated
at 4uC with 50 mL/well cell culture supernatants diluted 1:25 in
carbonate coating buffer (0.1 M Na2CO3, 0.1 M NaHCO3,
pH 9.5) at 4uC overnight. Standard curves were obtained with
purified recombinant human VEGF and bFGF (both from R&D
Systems) serially diluted in coating buffer (10-fold serial dilutions
from 1,000 to 0 ng/mL). After removing diluted supernatants or
standards, and blocking with PBS supplemented with 1% W/V
BSA for 1 h at RT, plates were incubated with mouse anti-human
VEGF or rabbit anti-human bFGF primary antibodies (2 mg/mL
in PBS, 50 mL/well Abcam, MA, USA) for 1 h at RT. Then,
plates were washed twice with PBS with 0.025% V/V Tween-20
(300 mL/well) and incubated at RT with anti-mouse or anti-rabbit
HRP-labeled secondary antibodies (0.2 mg/mL in PBS, 50 ml/
well; Abcam, Cambridge, MA, USA) for 1 h. The plates were
washed thrice with PBS containing 0.025% V/V Tween-20
(300 mL/well), the TMB colorimetric substrate (Thermo Fisher
Scientific, Waltham, MA , USA) was added, and after 5 min the
absorbance was measured (0.1 s) at 450 nm on a Victor 2
multimodal microplate reader (PerkinElmer, Billerica, MA, USA).
All samples were run in triplicates.
Generating AAV/GFP genome and virus stocks
The adeno-associated virus/green fluorescent protein (AAV/
GFP) genome was constructed as follows. Briefly, AAV/GFP virus
stocks were generated using complementary plasmids in s96-0.8 or
pSH3 in HEK293 cells. Lysates of HEK293 cells were used as
virus-negative control for mock infections. The DNA was
extracted from AAV/GFP virus crude lysates as the sample for
titer testing. The titers of virus stocks were determined by real-time
PCR. Briefly, we used the plasmid AAV/GFP for the real-time
PCR standards. Concentration was measured by absorbance at
260 nm. The real-time PCR was performed on an ABI Prism
7000 instrument (Applied Biosystems, Darmstadt, Germany) in a
50-ml reaction volume. Twenty ml of master PCR mix was
combined with 10-ml primers. Thermal cycling conditions were
as follows: 95uC for 10 min, 45 cycles of 95uC for 15 seconds, and
55uC for 1 min.
Testing Gal-3C and Bor in NOD/SCID subcutaneous
mouse model of MM
Prior to injection, U266 cells were washed once in Dulbecco’s
PBS (Sigma-Aldrich), counted, and adjusted to the appropriate
density with additional PBS. The suspension containing 1610
7
U266 cells was injected subcutaneously into the abdomen of naive
NOD/SCID mice. Primary tumors were measured with a pair of
calipers once a week. Tumor volume was calculated by the formula
width
26length60.5, where width was the smallest dimension.
The mice were randomly divided into four groups with five
mice in each group after 14 d. Control group #1 was
subcutaneously implanted in the abdomen with a PBS-only
containing 200-ml mini-osmotic pump. Group #2 received a dose
of Gal-3C (30 mg/d/mouse) subcutaneously over a 16-d period for
a total of 500 mg via a 200-ml mini-osmotic pump implanted
abdominally. Group #3 was treated with six doses of 15 mg Bor in
50-ml injections via the tail vein on d 1–2, 8–9, and 15–16 for a
total of 90 mg. Group #4 received Gal-3C via mini-pump for a
total dose of 500 mg Gal-3C (30 mg/d/mouse) plus a total 90 mg
Bor in 21 d. Anesthetized animals were euthanized and a post-
mortem examination was conducted on the whole animals and
dissected organs after 35 d.
Real-time PCR
Total RNA was extracted from the U266 cells, and cells from
tissue of the tumors, spleen, kidney, stomach, heart, lung and liver
by means of a Trizol-reagent (Sigma-Aldrich) and isolated with the
Oligotex mRNA Mini Kit (QIAGEN, Valencia, CA, USA), after
DNase I digestion. First-strand cDNA synthesis was performed
using oligo (dT) 15 primers. PCR primers were as follows: 59-
GCGTACTCTGATACTACAATGATG-39 and 59-GGG GTT-
TTGGGTAAAGTCA-39 for AKAP4; and 5- CGGTCGCCAC-
CATGGTGAGC-39 and 59-GAGCCGTACCTGCTCGACA-
TG-39 for GFP. The sizes of the primers were amplified for
AKAP4 to 1100 base pairs (bp) and for GFP to 730 bp,
respectively. Positive control was the cDNA of the U266 cells,
and negative control was the PCR reaction mixture with water in
place of cDNA. RNA integrity in each sample was checked by
amplification of a b-actin gene segment.
ELISA for human AKAP-4, IgG, E, k, and l light chain
Blood was collected from each mouse once a week, and an
ELISA was performed on the sera to quantify human AKAP-4,
IgG, IgE, k, and l light chain levels as reported [77]. Antibodies
for Igs were purchased from BD Biosciences. Anti AKAP-4
antibody was from Santa Cruz Biotechnology. Signal intensity was
measured on a Victor 2 multimodal microplate reader (PerkinEl-
mer, MA, USA) at 450 nm. All samples were run in triplicates.
Flow cytometric analysis
The expression of AKAP-4, human IgE, IgG, (heavy chain) k,
and l light chains was analyzed by cytofluorimetric techniques.
Briefly, cells from liver, blood, and tumor masses of animals from
each group were minced under sterile conditions at RT to obtain
single-cell suspensions. Minced tumor tissues were placed into 250-
ml flasks containing 3-ml of an enzyme solution that consisted of
0.14% collagenase type I (Sigma-Aldrich) and 0.01% DNase
(2000 kU/mg of tissue; Sigma-Aldrich) in RPMI 1640, and then
incubated on a magnetic-stirring apparatus at 37uC for 30 min.
Dissociated tissues were filtered through a 150-mm pore-size nylon
mesh to generate a single-cell suspension which was washed twice
in RPMI 1640 supplemented with 10% FBS and penicillin/
streptomycin.
Cell suspensions were distributed into 12675 mm tubes (5610
5
cells/tube). Cells were incubated with monoclonal antibodies
raised against human Ig and AKAP-4 or isotype matching
antibodies (BD Biosciences, CA, USA) as negative controls.
Analysis was performed using a fluorescence-activated cell scanner
(BD Biosciences).
Statistical analyses
All of the data are expressed as mean values, and as indicated
either6the standard error of the mean (SEM) or standard
deviation (S.D.). Results were analyzed using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego, CA,
USA). Univariate analyses were performed using a Student’s t test
as required for parametric variables with P,0.05 as the
significance limit.
Supporting Information
Figure S1 Viral vector used in the study and analysis of
infection. (A) A map of the AAV/GFP expression vector is
New Multiple Myeloma Treatment with Galectin-3C
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e21811presented. The restriction sites Xba I and Not I were used to insert
the GFP coding sequence. (B) The ligation of AAV genome and
GFP is shown by restriction digestion analysis. The GFP insert was
cut out from AAV/GFP by Xba I and Not I (lane 2). (C)
Quantification of virus titers by real-time PCR. DNA was
prepared from 1000-ml, 500-ml and 250-ml volumes of the cell
crude lysates of AAV/GFP-infected HEK293 cells and used as
template for real-time PCR. The titer was 10
8 encapsulated
genomes/ml. (D) Identification of U266 cells transduced with
AAV/GFP by flow cytometry. Grey and black histograms indicate
the fluorescence intensity distribution of AAV/GFP- and AAV-
transduced U266 cells, respectively. (E) RT-PCR for GFP
expression in transduced U266 cells. M: Marker, 1: AAV/GFP
plasmid, 2: No RT, 3: No template, 4: U266 cells transfected with
AAV/GFP. The size of the band from lane 4 was the same as the
lane 1. (F) Photomicrograph of U266 cells showing fluorescence of
AAV/GFP-transduced U266 cells.
(TIF)
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